Literature DB >> 32087187

Introduction: Novel insights into TB research and drug discovery.

Gerhard Grüber1.   

Abstract

Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), kills more people than any other bacterium. TB control is threatened by the continued spread of drug resistance; multi-drug and extensively drug resistant Mtb require longer, more costly, treatment with multiple drugs causing worse side effects and have a lower likelihood of treatment success. The urgent need for better treatment options for drug resistant Mtb has led the World Health Organization to prioritize development of not only new individual antitubercular agents, but also new drug regimens. This introductory chapter of the special issue Novel insights into TB research and drug discovery within Progress in Biophysics and Molecular Biology, gives a short overview about the general problems of TB and the treatment of this disease today, and introduces the review topics within this issue.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug discovery; Latent TB; Multi- and extensively drug resistance; Mycobacterium; Tuberculosis

Mesh:

Substances:

Year:  2020        PMID: 32087187     DOI: 10.1016/j.pbiomolbio.2020.02.003

Source DB:  PubMed          Journal:  Prog Biophys Mol Biol        ISSN: 0079-6107            Impact factor:   3.667


  5 in total

Review 1.  Handling the Hurdles on the Way to Anti-tuberculosis Drug Development.

Authors:  Pedro F Dalberto; Eduardo V de Souza; Bruno L Abbadi; Christiano E Neves; Raoní S Rambo; Alessandro S Ramos; Fernanda S Macchi; Pablo Machado; Cristiano V Bizarro; Luiz A Basso
Journal:  Front Chem       Date:  2020-11-19       Impact factor: 5.221

Review 2.  Recent Insights into the Structure and Function of Mycobacterial Membrane Proteins Facilitated by Cryo-EM.

Authors:  Ameya D Bendre; Peter J Peters; Janesh Kumar
Journal:  J Membr Biol       Date:  2021-05-05       Impact factor: 1.843

Review 3.  Tuberculosis: Past, present and future of the treatment and drug discovery research.

Authors:  Ameya D Bendre; Peter J Peters; Janesh Kumar
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-05-27

4.  A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation.

Authors:  Prakash Khadka; Jack Dummer; Philip C Hill; Rajesh Katare; Shyamal C Das
Journal:  Drug Deliv Transl Res       Date:  2022-09-21       Impact factor: 5.671

5.  Anti-tubercular activity and molecular docking studies of indolizine derivatives targeting mycobacterial InhA enzyme.

Authors:  Katharigatta N Venugopala; Sandeep Chandrashekharappa; Pran Kishore Deb; Christophe Tratrat; Melendhran Pillay; Deepak Chopra; Nizar A Al-Shar'i; Wafa Hourani; Lina A Dahabiyeh; Pobitra Borah; Rahul D Nagdeve; Susanta K Nayak; Basavaraj Padmashali; Mohamed A Morsy; Bandar E Aldhubiab; Mahesh Attimarad; Anroop B Nair; Nagaraja Sreeharsha; Michelyne Haroun; Sheena Shashikanth; Viresh Mohanlall; Raghuprasad Mailavaram
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.